JDRF Names Stephen L. Newman as Vice-Chairman of its International Board of Directors
New York, NY, September 10, 2014 —JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced today that Stephen L. Newman has been named Vice Chairman of the International Board of Directors (IBOD) for the organization, and will become a member of the Executive Committee.
Dr. Newman has been a member of JDRF’s IBOD for two years serving on the Advocacy and Finance Committees. He is retired Chief Operating Officer (COO) and Vice Chairman of Tenet Healthcare Corporation (THC) and is currently a Strategic Advisor at Gryphon Investors. Dr. Newman and his wife, Debbie, have been involved with JDRF since their daughter, Emilie, was diagnosed with T1D in 1983 at age five.
“We are thrilled to name Stephen Newman as our Vice-Chairman,” said John Brady, Chairman of the JDRF IBOD. “Steve’s dedication and leadership to JDRF and to all of our volunteers, donors and supporters is unwavering. He has been an integral part of the IBOD giving his time and talent. I am confident in his new role, Steve’s strategic insight and medical background will ensure our continued commitment to the vision of creating a world without T1D.”
“I have been committed to JDRF for more than 20 years, and am honored and excited about this next stage of my involvement with an organization that I’m so inspired and proud to be a part of,” said Newman. “I am eager to work closely with an incredibly talented board and management team as we work together to deliver life-changing treatments, and eventually a cure, for those living with T1D.”
As former COO for Tenet Healthcare Corporation, Dr. Newman was responsible for operational oversight of Tenet’s acute care hospitals, as well as ambulatory surgery centers and diagnostic imaging centers. From March 2003 until his promotion to COO in January 2007, Dr. Newman served as chief executive officer of Tenet’s California operations, building a successful, profitable core of hospitals in a highly competitive market. Dr. Newman joined Tenet in February 1999 as vice president of operations for Tenet’s former Gulf States Region, where he managed 12 hospitals in Alabama, Louisiana and Mississippi. In June 2000, he was promoted to senior vice president of operations.
Dr. Newman served as president and CEO of Columbia/HCA’s Louisville Healthcare Network, and is a member of the board of directors of Hansen Medical, Inc., and also currently serves on the Federal Reserve Bank of Atlanta’s Labor, Education and Healthcare Council and recently completed a five-year term on the board of directors of the Federation of American Hospitals.
In T1D, a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. People with T1D need to test their blood sugar and give themselves insulin (with injections or an insulin pump) multiple times every day, and carefully balance insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with that intensive care, a significant portion of the day is still spent with either high or low blood sugar, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence and a working plan to bring life-changing therapies from the lab to the community. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in charitable research in 17 countries. For more information, please visit visit jdrf.org.